Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEEL: Salvage Radiotherapy With Standard vs Enhanced ADT in Post-Prostatectomy PSA Recurrences
NCT03809000Phase 2Active, not recruiting
- Sponsor
- RTOG Foundation
- Start
- Apr 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of enzalutamide in prostate cancer (PCa), sponsored by RTOG Foundation. Started Apr 2019; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03809000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809000.